140 related articles for article (PubMed ID: 18564190)
1. Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A.
Martinowitz U; Lalezari S; Luboshitz J; Lubetsky A; Spira J
Haemophilia; 2008 Sep; 14(5):1122-4. PubMed ID: 18564190
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
Powell J; Martinowitz U; Windyga J; Di Minno G; Hellmann A; Pabinger I; Maas Enriquez M; Schwartz L; Ingerslev J;
Thromb Haemost; 2012 Nov; 108(5):913-22. PubMed ID: 23014711
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A.
Spira J; Plyushch OP; Andreeva TA; Khametova RN
Thromb Haemost; 2008 Sep; 100(3):429-34. PubMed ID: 18766258
[TBL] [Abstract][Full Text] [Related]
4. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
Meijer K; Rauchensteiner S; Santagostino E; Platokouki H; Schutgens RE; Brunn M; Tueckmantel C; Valeri F; Schinco PC
Haemophilia; 2015 Jan; 21(1):e19-25. PubMed ID: 25458982
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
Powell JS; Nugent DJ; Harrison JA; Soni A; Luk A; Stass H; Gorina E
J Thromb Haemost; 2008 Feb; 6(2):277-83. PubMed ID: 18039351
[TBL] [Abstract][Full Text] [Related]
6. Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasma-derived factor VIII.
Takedani H
Haemophilia; 2010 Sep; 16(5):740-6. PubMed ID: 20398072
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors.
Kasuda S; Tanaka I; Shima M; Matsumoto T; Sakurai Y; Nishiya K; Giles AR; Yoshioka A
Haemophilia; 2004 Jul; 10(4):341-6. PubMed ID: 15230947
[TBL] [Abstract][Full Text] [Related]
8. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy.
Baru M; Carmel-Goren L; Barenholz Y; Dayan I; Ostropolets S; Slepoy I; Gvirtzer N; Fukson V; Spira J
Thromb Haemost; 2005 Jun; 93(6):1061-8. PubMed ID: 15968389
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections.
Bidlingmaier C; Deml MM; Kurnik K
Haemophilia; 2006 May; 12(3):212-7. PubMed ID: 16643203
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan.
Yoshioka A; Shima M; Fukutake K; Takamatsu J; Shirahata A;
Haemophilia; 2001 May; 7(3):242-9. PubMed ID: 11380627
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A.
Young JH; Liu HC; Hsueh EJ; Huang ML; Peng CT; Chen RL; Maas-Enriquez M; Achilles K
Haemophilia; 2009 Jul; 15(4):968-70. PubMed ID: 19473407
[No Abstract] [Full Text] [Related]
12. In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A.
Revel-Vilk S; Blanchette VS; Schmugge M; Clark DS; Lillicrap D; Rand ML
Haemophilia; 2010 Jan; 16(1):72-9. PubMed ID: 19765092
[TBL] [Abstract][Full Text] [Related]
13. Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.
Hua B; Lee A; Fan L; Li K; Zhang Y; Poon MC; Zhao Y
Haemophilia; 2017 May; 23(3):417-421. PubMed ID: 28111886
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients.
Spira J; Plyushch O; Andreeva T; Zorenko V; Zozulya N; Velichkoi I; Zalepukhina OE; Yatuv R; Baru M
Br J Haematol; 2012 Jul; 158(1):149-52. PubMed ID: 22490119
[No Abstract] [Full Text] [Related]
15. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
16. To bleed or not to bleed - is that a question?
Aledort LM
J Thromb Haemost; 2010 Jan; 8(1):81-2. PubMed ID: 19874456
[No Abstract] [Full Text] [Related]
17. Infection risk and stability of a continuous 8-h 250 mL rFVIII infusion.
Lambing A; Kuriakose P; Mueller LM
Haemophilia; 2014 Mar; 20(2):212-8. PubMed ID: 24251950
[TBL] [Abstract][Full Text] [Related]
18. Use of factor VIII replacement during open heart surgery in a patient with haemophilia A.
Stine KC; Becton DL
Haemophilia; 2006 Jul; 12(4):435-6. PubMed ID: 16834747
[TBL] [Abstract][Full Text] [Related]
19. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
Manco-Johnson M
Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
[TBL] [Abstract][Full Text] [Related]
20. Successful surgery in severe haemophilia--a two-stage replacement therapy in resource-poor countries.
Prabhu R; Jijina F; Shetty S; Ghosh K
Haemophilia; 2008 Sep; 14(5):1125-6. PubMed ID: 18625030
[No Abstract] [Full Text] [Related]
[Next] [New Search]
